Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily ...

It was the day before Jessica Collier’s WHAT NUMBER birthday in December 2023 when she felt a lump in her breast. Immediately ...

City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Race does not significantly impact tumor mutations of triple-negative breast cancer, suggesting genetics and environmental ...

As we mark Breast Cancer Awareness month, work is being done in our own backyard to create better outcomes for patients.

The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...

Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

Patients with advanced triple-negative breast cancer who are ineligible for immunotherapy survived longer on Datroway than chemotherapy.

The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing ...

Positive high-level results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for ...

October 2025 Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer ...

Positive topline results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a ...